Innovent Expands Internationally With Indonesia Deal
Licensing Agreement Reached With Etana For Byvasda Bevacizumab Biosimilar
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
You may also be interested in...
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA.
An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.